Corpus ID: 27000520

Technology evaluation: SGN-15, Seattle Genetics Inc.

@article{Smith2001TechnologyES,
  title={Technology evaluation: SGN-15, Seattle Genetics Inc.},
  author={S. Smith},
  journal={Current opinion in molecular therapeutics},
  year={2001},
  volume={3 3},
  pages={
          295-302
        }
}
  • S. Smith
  • Published 2001
  • Biology, Medicine
  • Current opinion in molecular therapeutics
  • Seattle Genetics is developing SGN-15 (BMS-182248, BR96-DOX), a monoclonal antibody-doxorubicin conjugate licensed from Bristol-Myers Squibb (BMS) for the potential treatment of cancer, which is currently in phase II trials [283767], [305881], [391927]. BMS had licensed technology from Enzon to help antibodies such as SGN-15 penetrate tumors more efficiently [174538]. BMS also had an R&D agreement with Genzyme for the production of SGN-15 in transgenic goats milk [177921]. In 1993, Ixsys (now… CONTINUE READING
    7 Citations

    Topics from this paper

    Antibodies as therapeutic agents: vive la renaissance!
    • 78
    Monoclonal antibody–drug conjugates
    • 11
    Doxorubicin conjugates for selective delivery to tumors.
    • 14
    DNA and its associated processes as targets for cancer therapy
    • L. Hurley
    • Biology, Medicine
    • Nature Reviews Cancer
    • 2002
    • 1,025
    • PDF
    Natural products to drugs: natural product-derived compounds in clinical trials.
    • 649
    • PDF
    Antibody-Drug Conjugates
    • 1
    • Highly Influenced